The Aderans Research Institute (ARI), headquartered in Atlanta with a research facility in Philadelphia, is the research arm of two leading hair restoration companies: Aderans Holdings Co. Ltd., the world's leading manufacturer of wigs; and Bosley, the largest hair transplant company in the world.
ARI is pioneering one of the most hopeful paths of research in the field, a method of cellular hair regeneration referred to at ARI as the Ji Gami™ process. By rejuvenating hair-producing follicles, hair regeneration can generate an unlimited number of hairs from an individual's own hair cells.
Unlike competitive research, it's important to note the ARI techniques are entirely autologous. This means ARI only attempts to generate growth using cells from a participant's own hair. No plant- or animal-derived growth factors are introduced, thereby decreasing the likelihood of complications. When the cultivated cells are restored to the participant's scalp, he or she is receiving only his or her hair cells. Our serum-free process is unique to ARI and provides one of the most promising paths of research in the industry.
The ARI team comprises experienced professionals with advanced degrees in science, medicine and business. Meet our senior management.
Tadao Otsuki
President and Chief Operating Officer
Tadao assumed the position of President and Chief Operating Officer at Aderans Holdings on December 1, 2009. He brings more than 40 years of business experience in the consumer goods and professional services fields to Aderans Holdings.
Ken Washenik, MD, PhD
Executive Vice President,
Scientific and Medical Development
Ken is the former Director of the Dermatopharmacology unit at the New York University School of Medicine and former President of the North American Hair Research Society (NAHRS). A sought-after speaker and conference panelist in the field, Ken also serves as Medical Director of Bosley.
Kurt Stenn, MD
Vice President and Chief Scientific Officer
Kurt is one of the nation's preeminent scholars in the area of hair follicle research. He previously served for 10 years as the Director of Skin Biology at Johnson and Johnson. Prior to that, he was a full professor at Yale University for 20 years, as well as Director of Dermatopathology Laboratory Services at Yale.
Vern L. Liebmann
Vice President, Operations
Vern is a graduate of Columbia University and MIT. He is a former Vice President at C.R. Bard, a leading manufacturer of health care products. Vern has an extensive background in biomedical engineering, operations and marketing of medical products and services.
Dr. Anthony Atala MD, Wake Forest University
Dr. Cheng-Ming Chuong MD PhD, Univ. of Southern California
Dr. Leon Wilkins PhD, CytoProcess Consulting
Dr. Jeffrey Teumer PhD, Cell Therapy Consultant
